249 related articles for article (PubMed ID: 29790694)
41. The role of immunotherapy in small cell lung cancer.
Calles A; Aguado G; Sandoval C; Álvarez R
Clin Transl Oncol; 2019 Aug; 21(8):961-976. PubMed ID: 30637710
[TBL] [Abstract][Full Text] [Related]
42. Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.
Chae YK; Pan A; Davis AA; Mohindra N; Matsangou M; Villaflor V; Giles F
Clin Lung Cancer; 2017 Mar; 18(2):132-140. PubMed ID: 27520630
[TBL] [Abstract][Full Text] [Related]
43. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
[TBL] [Abstract][Full Text] [Related]
44. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
45. Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective.
Walia HK; Sharma P; Singh N; Sharma S
Curr Treat Options Oncol; 2022 Feb; 23(2):268-294. PubMed ID: 35226309
[TBL] [Abstract][Full Text] [Related]
46. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
[TBL] [Abstract][Full Text] [Related]
47. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Ott PA; Elez E; Hiret S; Kim DW; Morosky A; Saraf S; Piperdi B; Mehnert JM
J Clin Oncol; 2017 Dec; 35(34):3823-3829. PubMed ID: 28813164
[TBL] [Abstract][Full Text] [Related]
48. Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation.
Bonner JA; Willey CD; Yang ES; Dobelbower MC; Sanford LL; Bright SJ; Buchsbaum DJ; Raisch KP
Radiother Oncol; 2011 Oct; 101(1):183-9. PubMed ID: 21722984
[TBL] [Abstract][Full Text] [Related]
49. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
50. Evaluating
Lakes AL; An DD; Gauny SS; Ansoborlo C; Liang BH; Rees JA; McKnight KD; Karsunky H; Abergel RJ
Mol Pharm; 2020 Nov; 17(11):4270-4279. PubMed ID: 33044830
[TBL] [Abstract][Full Text] [Related]
51. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
[TBL] [Abstract][Full Text] [Related]
52. Effect of metformin in the prognosis of patients with smallcell lung cancer combined with diabetes mellitus.
Lu H; Xie F; Huang Z; Qin J; Han N; Mao W
Adv Clin Exp Med; 2018 Sep; 27(9):1195-1199. PubMed ID: 30016011
[TBL] [Abstract][Full Text] [Related]
53. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group.
Jalal S; Bedano P; Einhorn L; Bhatia S; Ansari R; Bechar N; Koneru K; Govindan R; Wu J; Yu M; Schneider B; Hanna N
J Thorac Oncol; 2010 Dec; 5(12):2008-11. PubMed ID: 21102263
[TBL] [Abstract][Full Text] [Related]
54. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study.
Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K
Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
57. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
[No Abstract] [Full Text] [Related]
58. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
[No Abstract] [Full Text] [Related]
59. A role for IGF-1R-targeted therapies in small-cell lung cancer?
Gately K; Collins I; Forde L; Al-Alao B; Young V; Gerg M; Feuerhake F; O'Byrne K
Clin Lung Cancer; 2011 Jan; 12(1):38-42. PubMed ID: 21273178
[TBL] [Abstract][Full Text] [Related]
60. Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis.
Han D; Wang G; Sun L; Ren X; Shang W; Xu L; Li S
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28707433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]